N-Phosphono-L-phenylalanine | 5652-25-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Phosphono-L-phenylalanine
• 英文别名: (2S)-3-phenyl-2-(phosphonoamino)propanoic acid
• CAS: 5652-25-5
• 化学式: C₉H₁₂NO₅P
• 分子量: 245.17
• InChiKey: VAZDOLJKYLURLC-QMMMGPOBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2931900090

文献信息

• Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus
  申请人：Doronina Svetlana O.

  公开号：US20090111756A1

  公开（公告）日：2009-04-30

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.

  具有C-末端苯丙氨酸羧基酸等效物的MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物已经制备，并通过各种连接剂（包括maleimidocaproyl-val-cit-PAB）连接到配体上。 结果得到的配体药物结合物在体外和体内均具有活性。
• METHODS OF USING MONOMETHYLVALINE COMPOSITIONS HAVING PHENYLALANINE CARBOXY MODIFICATIONS AT THE C-TERMINUS
  申请人：Seattle Genetics, Inc.

  公开号：US20150044238A1

  公开（公告）日：2015-02-12

  Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand-drug conjugates were active in vitro and in vivo in inhibiting cell proliferation and are represented by the general structure of L v -[(LU) 0-1 -(D) 1-4 ] p wherein L- is Ligand unit; LU is a Linker unit (LU); v is 1; p is an number ranging from about 1 to about 20; and D is a drug moiety having the formula: wherein the moiety —N(R 9 )Z 1 is a phenylalanine bioisostere, wherein Z 1 is —CH(R 10 )Z 2 so that the phenylalanine bioisostere has the structure of Formula A: and wherein the substituents R 2 -R 10 , X 1 and Z 2 are as defined.

  制备了具有C端苯丙氨酸羧酸等效物的MeVal-Val-Dil-Dap-Phe（MMAF）的Auristatin肽类类似物，并通过各种连接剂将其连接到配体上，包括maleimidocaproyl-val-cit-PAB。所得的配体-药物偶联物在体外和体内抑制细胞增殖方面具有活性，并由以下一般结构表示：Lv-[(LU)0-1-(D)1-4]p，其中L-是配体单元；LU是连接单元（LU）；v为1；p为约1至约20的数字；D是具有以下公式的药物基团：其中，—N（R9）Z1基团是苯丙氨酸生物同构体，其中Z1是—CH（R10）Z2，以便苯丙氨酸生物同构体具有A式结构；其中取代基R2-R10、X1和Z2如定义。
• Potassium channel blockers and use thereof in the treatment of autoimmune diseases
  申请人：MONASH UNIVERSITY

  公开号：US10246496B2

  公开（公告）日：2019-04-02

  Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal extension comprising an amino acid sequence according to formula (I): wherein X−4 is D, E or other negatively-charged amino acid or derivative thereof, X−3 is E, I, L, S, V, W or a tryptophan derivative, X−2 is any amino acid, X−1 is any amino acid, a is absent or a first additional moiety, and b is absent or a second additional moiety. a-X−4X−3X−2X−1-b(SEQ ID NO: 3)  (I)

  本发明公开了海葵螺旋藻毒素 ShK 的新型类似物及其用途，例如用作治疗自身免疫性疾病的治疗剂。这些类似物包括 ShK 毒素多肽和 N-末端延伸，N-末端延伸包括符合式（I）的氨基酸序列：其中 X-4 是 D、E 或其他带负电荷的氨基酸或其衍生物，X-3 是 E、I、L、S、V、W 或色氨酸衍生物，X-2 是任何氨基酸，X-1 是任何氨基酸，a 是缺失的或第一附加分子，b 是缺失的或第二附加分子。 a-X-4X-3X-2X-1-b(SEQ ID NO: 3) (I)
• ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY
  申请人：Novartis AG

  公开号：EP0846127A1

  公开（公告）日：1998-06-10
• METHODS AND REAGENTS FOR DETERMINING ENZYME SUBSTRATE SPECIFICITY, AND USES RELATED THERETO
  申请人：TRUSTEES OF TUFTS COLLEGE

  公开号：EP1169470A1

  公开（公告）日：2002-01-09